Evidence map›Paper›PMID 34830327›Full record

ArticleInternational journal of molecular sciences2021

Biochemical Characterisation of Human Transglutaminase 4.

Zsuzsa Csobán-Szabó, Bálint Bécsi, Saïd El Alaoui, László Fésüs, Ilma Rita Korponay-Szabó, Róbert Király

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Zsuzsa Csobán-SzabóDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Bálint BécsiDepartment of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Saïd El AlaouiResearch Department, Covalab S.A.S., 69500 Bron, France.
László FésüsDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0002-3338-2362
Ilma Rita Korponay-SzabóDepartment of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Róbert KirályDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0002-1606-3132
University of Debrecen · HUCovalab (France) · FR

Funding

European Union and the European Regional Development Fund GINOP-2.3.2-15-2016-00015European Union and the European Regional Development Fund GINOP-2.3.3-15-2016-00020National Research, Development and Innovation Office of Hungary NKFIH-K120392National Research, Development and Innovation Office of Hungary NKFIH-K129139
6 · The paper itself

Abstract

Transglutaminases are protein-modifying enzymes involved in physiological and pathological processes with potent therapeutic possibilities. Human TG4, also called prostate transglutaminase, is involved in the development of autoimmune and tumour diseases. Although rodent TG4 is well characterised, biochemical characteristics of human TG4 that could help th e understanding of its way of action are not published. First, we analysed proteomics databases and found that TG4 protein is present in human tissues beyond the prostate. Then, we studied in vitro the transamidase activity of human TG4 and its regulation using the microtitre plate method. Human TG4 has low transamidase activity which prefers slightly acidic pH and a reducing environment. It is enhanced by submicellar concentrations of SDS suggesting that membrane proximity is an important regulatory event. Human TG4 does not bind GTP as tested by GTP-agarose and BODIPY-FL-GTPγS binding, and its proteolytic activation by dispase or when expressed in AD-293 cells was not observed either. We identified several potential human TG4 glutamine donor substrates in the AD-293 cell extract by biotin-pentylamine incorporation and mass spectrometry. Several of these potential substrates are involved in cell-cell interaction, adhesion and proliferation, suggesting that human TG4 could become an anticancer therapeutic target.

Indexed as

Amino Acid SequenceCell Line, TumorCloning, MolecularColonEnzyme StabilityEpithelial CellsEscherichia coliGene ExpressionGenetic VectorsHumansHydrogen-Ion ConcentrationKineticsMaleMyocardiumProstateRecombinant ProteinsRecombinant ProteinsSodium Dodecyl Sulfatetransglutaminase 4Transglutaminasesdatabase reanalysisenzyme activityprostate cancerprotein crosslinkingproteomic analysissubstrate searchTG4TGptissue distributiontransglutaminase

Identifiers

PMID34830327
PMCPMC8619550
OpenAlexW3215847131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.